Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

EP: 1.Navigating mCRC: Treatment Options in the Third-Line Setting

EP: 2.Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP: 3.Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

Now Viewing

EP: 4.Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP: 5.Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP: 6.Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP: 7.Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP: 8.Unmet Needs in Third-Line mCRC: Challenges and Opportunities

1. What are your perspectives regarding the SUNLIGHT trial?
   1. Does this trial design with an active-arm comparator arm compared with trials utilizing a placebo-controlled comparator (eg, FRESCO-2, CORRECT) impact or influence your treatment approach? If so, how
2. Are there certain efficacy outcomes between these agents that have a greater influence or impact on your decision-making?
   

Related Videos